We are excited to announce AICURA medical’s participation in this year’s Clinical Trials on Alzheimer’s Disease (CTAD) 2025 conference, taking place in San Diego, California. Our team will present new research on accelerating AI-driven clinical development using a scalable, multimodal data platform designed specifically for the complexities of Alzheimer’s disease (AD) research.

Our Chief Medical Officer, Janis Reinelt, will be attending the conference and presenting our latest research in collaboration with Neurimmune. He will be available during the poster sessions on Monday, December 1 (3:00 p.m.) and Tuesday, December 2 (5:30 p.m.), where he will present Poster P142, titled “Efficient Clinical Development and Research via an AI-Ready Multimodal Data Platform.”

This research showcases how the AICURA Data Layer leverages data harmonization to integrate large-scale multimodal datasets. This includes imaging, biomarkers, clinical assessments, and open-source datasets such as ADNI, all unified into an AI-ready patient view. By removing data engineering bottlenecks, the platform enables multimodal AI development, significantly reducing timelines, and supporting more efficient, scalable clinical research in Alzheimer’s disease.

We invite you to visit Poster P142 to learn more about our AI-ready multimodal data platform and its potential to accelerate and de-risk clinical trials. Janis will be available throughout the session to discuss collaboration opportunities and answer questions.

If you are not attending CTAD 2025 and would like to learn more, request an introduction today to discover how AICURA can support your clinical development programs.